Roche and Prothena to Advance Prasinezumab in P-IIb Study for Patients with Early Parkinson’s Disease
Shots: The companies will advance the prasinezumab into a P-IIb study in patients with early Parkinson’s disease based on positive signals of efficacy consistent with disease modification in the PASADENA study The study is designed to further assess the efficacy of prasinezumab by expanding upon the patient population enrolled in PASADENA study to include patients […]